Cas 868052-23-7,(E)-3-{ 4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-prop-2-en-1-ol

868052-23-7

Post Buying Request

Basic information

Product Name: (E)-3-{ 4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-prop-2-en-1-ol
Synonyms: (E)-3-{ 4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-prop-2-en-1-ol
CAS NO:868052-23-7
Molecular Formula:
Molecular Weight: 345.828
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: (E)-3-{ 4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-prop-2-en-1-ol(CAS DataBase Reference)
NIST Chemistry Reference: (E)-3-{ 4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-prop-2-en-1-ol(868052-23-7)
EPA Substance Registry System: (E)-3-{ 4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-prop-2-en-1-ol(868052-23-7)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 868052-23-7(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

868052-23-7 Suppliers

Recommended suppliers

868052-23-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 868052-23-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,8,0,5 and 2 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 868052-23:
(8*8)+(7*6)+(6*8)+(5*0)+(4*5)+(3*2)+(2*2)+(1*3)=187
187 % 10 = 7
So 868052-23-7 is a valid CAS Registry Number.

868052-23-7Upstream product

868052-23-7Downstream Products

868052-24-8 5-(4-chloro-phenyl)-2-[4-((E)-3-chloro-propenyl)-phenylethynyl]-pyridine

868052-23-7Relevant academic research and scientific papers

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

-

Page/Page column 39, (2010/02/14)

The present invention relates to alkyne compounds of general formula I wherein the groups and radicals A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one alkyne according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

-

Page/Page column 35, (2010/02/14)

Alkyne compounds of formula I wherein A, B, W, X, Y, Z, R1, and R2 have the meanings given herein, which have MCH-receptor antagonistic activity and are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS CONTAINING SAID COMPOUNDS

-

Page/Page column 91, (2010/02/14)

The invention relates to alkyne compounds of general formula (I), in which the groups and radicals A, B, W, X, Y, Z, R1 and R2 are defined as cited in claim 1. The invention also relates to medicaments containing at least one inventive alkyne. As a result of the antagonistic action against the MCH-receptor, the inventive medicaments are suitable for treating metabolic disorders and/or eating disorders, in particular adiposity and diabetes.

NOVEL ALKYNE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, AND MEDICAMENTS CONTAINING SAID COMPOUNDS

-

Page/Page column 93, (2010/02/14)

The invention relates to alkyne compounds of general formula (I), wherein the groups and radicals A, B, W, X, Y, Z, R1, and R2 have the meanings indicated in claim 1. The invention further relates to medicaments containing at least one inventive alkyne. The disclosed medicaments are suitable for the treatment of metabolic disorders and/or eating disorders, particularly adiposity and diabetes, as a result of the MCH receptor antagonistic activity thereof.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 868052-23-7